Filterable News List

Calabasas, California and Abu Dhabi, United Arab Emirates - NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system cancers, has signed a Memorandum of Understanding (MoU) with the Department of Health - Abu Dhabi (DoH). The agreement aims to advance research and clinical capabilities in oncology and central nervous system therapeutics within the Emirate.

The proposed collaboration covers scientific and clinical exchange, specialist training, real-world evidence generation, and the assessment of clinical trial opportunities. Additionally, the partnership will explore a potential regional presence and manufacturing or distribution activities for NeOnc in Abu Dhabi.

Key Highlights

• Signing of an MoU between NeOnc and the Department of Health - Abu Dhabi during the Abu Dhabi Future Health Summit 2026.
• Focus on scientific exchange, specialist training, and clinical development methodologies for brain cancer and CNS tumors.
• Ongoing Compassionate Care program treating children in Abu Dhabi with investigational NEO100.
• Plans to work towards opening a Phase 1 study of NEO100 in the Emirate following prior Investigational New Drug status grants.

Tokyo and New York - Advasa Holdings, Inc. (Nasdaq: ADBT), a fintech payment holding company delivering Earned Wage Access and financial infrastructure solutions, announced that Mr. Asamitsu Kosugi, the Company's largest stockholder, has expressed his intention to surrender 97,413,140 shares of common stock to the company for no consideration.The surrendered shares represent approximately 20% of…

… Read on — Pro Members

Burlington, Mass., USA - Fractyl Health, Inc. (Nasdaq: GUTS), a clinical-stage metabolic therapeutics company, announced a strategic reprioritization to concentrate its resources on advancing Revita toward a planned FDA De Novo submission in post-GLP-1 weight maintenance.

The decision follows positive topline six-month results from the REMAIN-1 pivotal cohort, which met its prespecified co-primary endpoint. To support this focus, the company is implementing a workforce reduction of approximately 45%, discontinuing internal development of its Rejuva gene therapy program, and seeking strategic alternatives for it. These measures are expected to reduce quarterly cash burn by about 50% and extend the cash runway into the second quarter of 2027.

Key Highlights

• Planned FDA De Novo submission for Revita in late Q4 2026.
• Anticipated 12-month pivotal data readout in Q1 2027.
• Workforce reduction of approximately 45% to align organization behind Revita.
• Operating cash burn expected to drop to approximately $8 million by the end of Q2 2027.

New York, NY Critical Metals Corp. (Nasdaq: CRML) provided an update on its proposed acquisition of European Lithium Limited (ASX: EUR, FRA: PF8, OTC: EULIF) ahead of the European Lithium securityholder meetings scheduled for October 22, 2026.

Under the transaction, Critical Metals Corp will acquire 100 percent of the issued share capital of European Lithium and all listed options through Court-approved schemes of arrangement. European Lithium shareholders will receive 0.045 new Critical Metals Corp shares for each European Lithium share held at the record date, based on the established Share Scheme Transaction Ratio.

Transaction Details

• Acquisition of 100 percent of European Lithium issued share capital and listed options.
• Share Scheme Transaction Ratio set at 0.045 new Critical Metals Corp shares per European Lithium share.
• Consideration value subject to Critical Metals Corp share price and AUD/USD exchange rate.
• Securityholder meetings to vote on the schemes scheduled for October 22, 2026, in West Leederville, Western Australia.

Hagerstown, MD, USA - First Breach Inc. (NASDAQ:FBDT), an American defense technologies company, announced that its proprietary drone prototype has reached a speed of 161 km/h (100 mph) in flight testing without a payload.The achieved speed represents the maximum groundspeed permitted by the Federal Aviation Administration for small unmanned aircraft under Part 107 without a…

… Read on — Pro Members

Hagerstown, Maryland, USA - First Breach Inc. (NASDAQ:FBDT), a defense technologies company specializing in vertically integrated ammunition production and next-generation unmanned aerial systems, announced that Chief Revenue Officer Ken Leith will present at the 20th Annual LD Micro Main Event.The conference is scheduled to take place from October 19 to 21, 2026, at the Luxe…

… Read on — Pro Members

NEW YORK, NEW YORK, USA - Pine Tree Acquisition Corp. announced that holders of its units sold in the company's initial public offering may elect to separately trade the company's Class A ordinary shares and rights starting on or about October 23, 2026.The separated Class A ordinary shares and rights will trade on the Nasdaq…

… Read on — Pro Members

Singapore and Houston, October 21, 2026 - GOWell Energy Technology, a global provider of innovative well-logging solutions in the energy sector, announced the financial results of its operating subsidiary, GOWell Technology Limited, for the first half of 2026. The company also reiterated its full-year 2026 financial guidance.Financial HighlightsRevenue: Reached $33.8 million in the first half…

… Read on — Pro Members

Space Exploration Technologies Corp. (Nasdaq: SPCX) released its financial results for the third quarter ended September 30, 2026, showcasing significant year-over-year revenue growth driven by its Connectivity and Super Intelligence segments.

Financial Performance

During the third quarter of 2026, SpaceX delivered total revenue of $14.6 billion, representing a 161 percent increase compared to the same period in the previous year. The company posted an operating income of $2.8 billion, a net income of $4.4 billion, and an Adjusted EBITDA of $8.8 billion.

The strong financial results were largely fueled by accelerated growth in the Connectivity segment and a clear inflection in the Super Intelligence (SI) business. Connectivity revenues reached $5.2 billion, while SI revenues contributed $7.6 billion to the quarterly total.

Financial Highlights

• Total Revenue: $14.6 billion, up 161% year-over-year
• Net Income: $4.4 billion, improving from a net loss of $1.1 billion
• Adjusted EBITDA: $8.8 billion, up 306% year-over-year
• Connectivity Segment Revenue: $5.2 billion, up 69% year-over-year
• Super Intelligence Segment Revenue: $7.6 billion, up 830% year-over-year

BRISBANE, Calif., USA -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company, announced the launch of the SimpleScreen Lung test alongside a first-of-its-kind offering that allows eligible patients to be screened for both lung and colorectal cancer (CRC) through a single blood draw. The company's Personalized Cancer Detection (PCD) approach combines risk-based screening with indication-specific tests tailored to individual patient needs.

SimpleScreen Lung is designed for adults aged 50 to 80 with a significant smoking history who are not currently up to date with standard-of-care screening. It can be ordered independently or combined with the FDA-approved SimpleScreen CRC test for patients eligible for both screenings.

Key Highlights

• SimpleScreen Lung demonstrated 85% sensitivity at 50% specificity and a 99.8% negative predictive value in an independent validation cohort.
• The dual-screening option enables patients to address multiple cancer screening requirements in a single clinical encounter, aiming to improve overall participation rates.
• SimpleScreen CRC is FDA-approved for average-risk adults aged 45 and older.